BEIJING--(BUSINESS WIRE)--Jul 3, 2025-- The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ: SVA) (“ SINOVAC ” or the “ Company ”), a leading provider of biopharmaceutical products in China, today announced that leading independent proxy advisory firm Institutional Shareholder Services Inc. (“ISS”) has joined Glass, Lewis & Co. (“Glass Lewis”) in recommending that SINOVAC shareholders vote to KEEP the current SINOVAC Board in place by voting the WHITE proxy card “AGAINST” the election of the Reconstituted Imposter Former Board Slate at the upcoming Special Meeting of Shareholders (the “Special Meeting”). The SINOVAC Board issued the following statement in response to ISS’ recommendation: “We are thrilled that independent proxy advisors ISS and Glass Lewis recommended shareholders vote to KEEP SINOVAC’s current Board in place and OPPOSE the Reconstituted Imposter Former Board Slate. In making their recommendations, ISS and Glass Lewis both recognized the swift actions the current SINOVAC Board has taken to restore fairness and deliver value to SINOVAC’s rightful shareholders, and they have criticized the Imposter Former Board’s abject governance failures that robbed value from SINOVAC shareholders during its seven-year “de facto” tenure.